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The American Society of Transplant Surgeons (ASTS)
champions efforts to increase organ donation. Con-
trolled donation after cardiac death (DCD) offers the
family and the patient with a hopeless prognosis the
option to donate when brain death criteria will not
be met. Although DCD is increasing, this endeavor is
still in the midst of development. DCD protocols, re-
covery techniques and organ acceptance criteria vary
among organ procurement organizations and trans-
plant centers. Growing enthusiasm for DCD has been
tempered by the decreased yield of transplantable or-
gans and less favorable posttransplant outcomes com-
pared with donation after brain death. Logistics and
ethics relevant to DCD engender discussion and de-
bate among lay and medical communities. Regula-
tory oversight of the mandate to increase DCD and
a recent lawsuit involving professional behavior dur-
ing an attempted DCD have fueled scrutiny of this ac-
tivity. Within this setting, the ASTS Council sought
best-practice guidelines for controlled DCD organ do-
nation and transplantation. The proposed guidelines
are evidence based when possible. They cover many
aspects of DCD kidney, liver and pancreas transplan-
tation, including donor characteristics, consent, with-
drawal of ventilatory support, operative technique,
ischemia times, machine perfusion, recipient consid-
erations and biliary issues. DCD organ transplantation
involves unique challenges that these recommenda-
tions seek to address.
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Introduction
The American Society of Transplant Surgeons (ASTS)
champions efforts to increase the number of organs that
are available for critically needed transplants. One impor-
tant effort involves transplantation of donation after car-
diac death (DCD) organs and improving outcomes of these
transplants. This goal is particularly relevant because DCD
donors have been shown to be a potential source of trans-
plantable organs that has yet to be fully utilized (1,2). Car-
diac death is defined as ‘irreversible cessation of circulatory
and respiratory function’ (1–5). Controlled DCD involves
planned withdrawal of ventilatory and organ-perfusion sup-
port in the face of catastrophic illness (Maastricht III),
whereas uncontrolled DCD involves unexpected cardiopul-
monary arrest and/or unsuccessful resuscitation (Maas-
tricht I, II, IV) (1–6). Controlled DCD offers the patient and
the family the opportunity to donate when criteria for brain
death declaration will not have been met prior to cardiac
death. It should be emphasized that whether or not organ
donation is to be pursued, such patients’ legal decision
maker(s) elect to withdraw ventilatory support because of
a hopeless prognosis. The transplant community has no
say in whether or when support will be withdrawn. Fur-
thermore, it must be recognized that the patient who is
considered for DCD is not dead and not a donor unless
and until he or she should die.
Growing enthusiasm about the option of DCD organ pro-
curement ought to be tempered by the realization that both
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Donation after Cardiac Death: Best Practices
the yield of transplantable organs from DCDs and the out-
comes after DCD organ transplantation are not generally
as favorable as those with donation after brain death (DBD)
organs (7–19). DCD shall not be viewed as an equally
acceptable alternative to DBD because DCD on average
yields fewer organs and the organs probably have more
risk than organs recovered from DBD donors (7–12,14–19).
The relative risks and benefits of DCD organ transplanta-
tion are being established. The safety of various DCD pro-
tocols and organ procurement and transplant techniques is
being evaluated. DCD should be considered only when the
DCD option might genuinely expand the organ donor pool
because DBD organ procurement will not be possible. Reg-
ulatory oversight of the mandate to increase DCD (20) and
a recent, highly publicized lawsuit involving professional be-
havior during an attempted DCD (21) have fueled scrutiny
of this activity. The following recommendations regarding
controlled DCD of abdominal organs and their transplan-
tation represent expert opinion and are evidence based
when possible (Table 1). They are practice guidelines that
can be adopted by transplant surgeons and centers and
can be individualized as needed. It is the expectation of
the ASTS that these recommendations may require mod-
ification in the future, as innovations designed to improve
outcomes are explored and implemented.
Methods
The ASTS Council requested that the Standards on Organ Transplantation
Committee propose best-practice guidelines for controlled DCD abdominal
organ procurement and transplantation. A work group composed of com-
mittee members and additional experts in DCD prepared a list of topics that
the recommendations should cover, performed a computerized search of
the National Library of Medicine for English language citations from 1990
through 2008 using the words ‘donation after cardiac death’ and ‘non-heart-
beating donor’ and drafted guidelines. Suggested revisions were solicited
from each member of the work group, committee and Council. The authors
of this manuscript collaborated in editing the guidelines.
The Oxford Centre grading scheme was used to rate the level of scientific
evidence of each reference cited in these guidelines (22). Individual ratings
and a summary of the grading scheme are provided in the Table 1. These
practice guideline recommendations should be supplemented with infor-
mation obtained by consulting the literature citations provided. Efforts have
been made in preparing these guidelines to strive for consistency with rec-
ommendations and practice guidelines on DCD published by other groups
(1–3,23–27).
Recommendations
DBD provides superior transplant outcomes
compared with DCD
• Given that outcomes after DCD are generally infe-
rior to those after DBD, it is strongly preferred that
organ donation be pursued according to DBD rather
than DCD protocols when encountering potential or-
gan donors who are brain dead or who will likely soon
become so.
∗ Compared with DBD, DCD provides a lower yield
of transplantable organs (7,8), liver recipients with de-
creased patient and graft survivals rates and increased
risk of ischemic biliary complications (9–16) and kidney
recipients with increased risk of delayed graft function
(17–19), although DCD kidneys from otherwise stan-
dard criteria donors provide survival outcomes similar
to those of DBD kidneys (24).
• A consenting potential organ donor’s family, legal deci-
sion maker(s) and healthcare providers shall be encour-
aged to facilitate completion of a brain death protocol
when brain death seems present, even if such pro-
tocols might be viewed as cumbersome when com-
pared with DCD protocols. If brain death seems immi-
nent, they shall be given the opportunity to wait rather
than pursue DCD.
• DCD can provide genuine expansion of the organ
donor pool if DBD is not feasible, such as when (a)
there is catastrophic injury but brain death is not im-
minent and there is a request for withdrawal of ven-
tilatory and organ-perfusion support or (b) completion
of a brain-death protocol with a seemingly brain-dead
or soon to be brain-dead potential organ donor is pre-
cluded because of severe hemodynamic instability or
because the family/legal decision maker(s) will not
wait for completion of a brain-death protocol.
• In cases where progression to brain death might
occur, consent from family/legal decision maker(s)
should include the possibility of conversion to DBD
from DCD should progression occur (23).
DCD protocols
• Ensure that the organ procurement organization
(OPO) and transplant center have approved, detailed
DCD protocols and hospital development processes
in place (1–3,23–28).
• Ensure that the transplant team members are familiar
with DCD protocols and with relevant ethical princi-
ples.
• Ensure that the transplant team members are not in-
volved in decisions related to patient prognosis, with-
drawal of ventilatory or organ-perfusion support or de-
termination of death, because each would represent
a conflict of interest (1–3,5,23–27). In a situation in
which a transplant team member has cared for a pa-
tient who is being considered for DCD, such as in the
role of a critical care or trauma specialist, the team
member should transfer care of the patient to another
individual and separate him- or herself from any fur-
ther involvement with the patient, including involve-
ment related to patient prognosis and decisions about
withdrawal of ventilatory or organ-perfusion support;
this transplant team member may then participate in
DCD organ procurement.
• Uncontrolled DCD donors are substantially different
from controlled DCD donors (Maastricht I, II, IV vs.
Maastricht III) (1–3). Organs from uncontrolled DCD
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Table 1: The level of evidence for each reference cited in these draft guidelines, based on the Oxford Centre grading scheme (22)
Reference Authors Organ Major focus
Level of evidence: B
7 Sung RS et al. All Organ donation and utilization (SRTR)
8 Merion RM et al. Liver DCD livers: increased use and increased risk of graft failure (SRTR)
9 Freeman Jr RB et al. Liver DCD livers: increased use and increased risk of graft failure (SRTR)
10 Abt PL et al. Liver DCD livers prone to graft failure, especially with longer cold
ischemia or unstable recipients (UNOS)
11 Lee KW et al. Liver Risk factors for DCD LTX, including older DCDs and longer ischemia
times (UNOS)
12 Mateo R et al. Liver Risk factors for DCD LTX, including longer ischemia times and high
risk recipients (UNOS)
13 Foley DP et al. Liver DCD LTX: increased patient and graft loss and biliary complications
(University of Wisconsin, Madison, WI)
14 Abt P et al. Liver DCD LTX prone to biliary complications (University of Pennsylvania,
Philadelphia, PA)
17 Rudich SM et al. Kidney DCD KTX outcomes same as DBDs, except for increased DGF
(USRDS)
18 Weber M et al. Kidney DCD KTX outcomes same as DBDs, except for increased DGF
(University of Zurich, Switzerland)
19 Locke JE et al. Kidney Risk factors for DCD KTX, including age >50 years and CIT >12 h
(UNOS)
29 Otero A et al. Liver Uncontrolled (Maastricht II) DCD LTX (Spain)
30 Suárez F et al. Liver Uncontrolled (Maastricht II) DCD LTX: increased biliary
complications (Spain)
31 Sanchez-Fructuoso AI et al. Kidney Uncontrolled (Maastricht II) DCD KTX (Spain)
38 Fernandez LA et al. Kidney,
pancreas
DCD SPK outcomes same as DBDs, except for increased renal DGF
(University of Wisconsin, Madison, WI)
42 Guichelaar MM et al. Liver Risk factors for nonanastomotic biliary strictures post-LTX, including
longer ischemia times (Mayo Clinic, Rochester, Minnesota)
43 Sankary HN et al. Liver Simultaneous hepatic artery and portal vein revascularization
protects against nonanastomotic biliary strictures post LTX (Rush
University, Chicago, IL)
Level of evidence: C
15 Lee HW et al. Liver Classification of biliary strictures after DCD LTX (Seoul, Korea)
16 Maheshwari A et al. Liver Biliary complications after DCD LTX (Johns Hopkins University,
Baltimore, MD)
32 Casavilla A et al. Liver,
kidney
Super rapid recovery technique and DCD LTX and KTX (University of
Pittsburgh, PA)
34 D’Alessandro AM et al. All Premortem cannulation technique and DCD organ transplantation
(University of Wisconsin, Madison, WI)
35 Magliocca JF et al. All ECMO and DCD organ recovery (University of Wisconsin, Madison,
WI)
36 Jeon H et al. Pancreas Surgical techniques for procuring DCD pancreas in addition to liver
(Albert Einstein Medical Center, Philadelphia, PA)
37 Muiesan P et al. Liver DCD LTX provided safe donor pool expansion (King’s College
Hospital, London, UK)
41 Buis CI et al. Liver Risk factors for nonanastomotic biliary strictures (University of
Groningen, The Netherlands)
44 Snell GI et al. Lung DCD lung transplantation (Melbourne, Australia)
45 Boucek MM et al. Heart DCD heart transplantation (Denver Children’s Hospital, Colorado)
Level of evidence: D
1 Institute of Medicine All DCD history, ethics, medical issues and policies
2 Institute of Medicine All How to facilitate DCD protocol development and practice
3 Institute of Medicine All Current and potential rates of uncontrolled and controlled DCDs
4 Kootstra G All DCD overview
5 Arnold RM et al. All Ethical and public policy implications of procuring DCD organs
6 Kootstra G et al. All Maastricht categories of DCDs
20 Federal Register All Requirements for OPOs providing DCD
21 The Wall Street Journal All Lawsuit involving DCD
23 UNOS All Critical pathway for DCD
Continued.
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Table 1: Continued
Reference Authors Organ Major focus
24 Bernat JL et al. All U.S. consensus conference recommendations about DCD
25 Society of Critical Care Medicine All Recommendations for DCD policies
26 OPTN Bylaws All Model elements for DCD protocols
27 UNOS All Reference guide for DCD
28 Arnold RM et al. All Need for DCD policies
33 Reich DJ All Surgical techniques for procuring DCD organs
39 Federal Register All Requirement to disclose to patient risks and benefits of
transplantation
40 Reich DJ et al. Liver Textbook chapter on DCD LTX
CIT = cold ischemia time; DBD = donation after brain death; DCD = donation after cardiac death; DGF = delayed graft function; ECMO =
extracorporeal membrane oxygenation; KTX = kidney transplantation; LTX = liver transplantation; OPO = organ procurement organization;
SPK = simultaneous pancreas and kidney transplantation; SRTR = Scientific Registry of Transplant Recipients; UNOS = United Network
for Organ Sharing; USRDS = United States Renal Data System.
A brief summary of the Oxford Centre grading scheme follows (see reference 20 for detailed criteria):
Level A—consistent randomized controlled clinical trial or cohort study (as yet, there is no level A reference on DCD).
Level B—consistent retrospective cohort, exploratory cohort, outcomes research, case–control study or extrapolations from level A
studies.
Level C—case-series study or extrapolations from level B studies.
Level D—expert opinion without explicit critical appraisal.
donors may pose different risks than those from con-
trolled DCD donors (29–31). Principles of consent
for donation and interventions prior to declaration of
death may be significantly different for uncontrolled
and controlled DCD (3).
Potential DCD donor characteristics (1–3,23–27)
• Medically suitable for donation
• Brain death criteria not met (except in rare cir-
cumstances), although a potential DCD donor may
progress to become a DBD donor
• Catastrophic brain injury or other illness such as end-
stage musculoskeletal disease, pulmonary disease or
high spinal cord injury
• No expectation of meaningful survival, as determined
by the patient’s treating physician(s); request for with-
drawal of ventilatory and organ-perfusion support by
the patient’s legal decision maker(s) and/or by properly
executed prior first-party declarations by the potential
donor.
• Informed consent obtained from the patient’s legal de-
cision maker(s) (obtained after decision to withdraw
support): the possibility that the patient may not die
or may not provide transplanted organs shall be com-
municated to the patient’s legal decision maker(s) as
a component of the informed consent process, as
well as to operating room and other relevant hospital
personnel, before withdrawal of ventilatory or organ-
perfusion support.
Withdrawal of ventilatory and organ-perfusion
support
• Optimally, withdrawal of ventilatory and organ-
perfusion support will occur in the operating room.
However, it is recognized that this is not always pos-
sible and that OPO efforts to facilitate the potential
DCD donor’s family wishes shall be supported.
• The family can be given the opportunity to spend
time with the patient immediately prior to and dur-
ing discontinuation of support and until cessation of
cardiorespiratory function.
• Heparin shall be administered, prior to withdrawal of
support, except in the rare case when it might be
expected to hasten death and/or is prohibited per lo-
cal procurement protocol (3,23,24,26). Phentolamine
may be administered per local procurement protocol
as long as it is not expected to hasten death. Spe-
cific informed consent for administration of each of
these agents shall be obtained from the patient’s le-
gal decision maker(s) prior to withdrawal of support
(3,23,24,26).
• Morphine and/or other analgesics may be given at
the discretion of the patient’s treating care team if
the purpose is to minimize discomfort in a dying pa-
tient according to accepted end-of-life protocols, even
if this might hasten death as an unintended conse-
quence. Procurement team members shall not partic-
ipate in decisions regarding the use of such agents
(3,23,24,26).
• Members of the procurement team may be present
prior to withdrawal of ventilatory and organ-perfusion
support to prepare and drape the patient. During such
preparation and draping, it is critical to recognize that
the potential DCD donor is a patient who is still alive.
• Members of the procurement team shall not be in the
presence of the patient at the time of withdrawal of
support and until the declaration of death (this includes
absence during withdrawal of ventilatory and organ-
perfusion support, until the time of cardiorespiratory
arrest, and through the waiting period until declaration
of death—see below) (23,26).
• The patient’s treating care team stops ventilation.
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• The patient’s treating care team monitors the patient
and notes the time of cessation of cardiorespiratory
function.
• Subsequently, a waiting period is observed prior to
declaration of death to ensure that autoresuscitation
does not occur. In as much as autoresuscitation has
not been reported after 2 min (3,24), the ASTS recom-
mends a 2-min waiting period in order not to unnec-
essarily increase warm ischemia time. However, the
ASTS recognizes that a range of waiting period dura-
tions have been endorsed, primarily because data on
autoresuscitation are limited. The Society of Critical
Care Medicine recommends at least 2 min of obser-
vation (25) and the Institute of Medicine recommends
5 min (1–3). Until additional information is available,
the duration of the waiting period shall be compliant
with local OPO and donor hospital policies (2- to 5-min
period).
∗ Some DCD policies define the waiting period as a
‘time-out’ period after declaration of death. Whether
declaration of death in the DCD setting requires a prior
waiting period (following cessation of cardiorespira-
tory function) or such declaration requires a subse-
quent time-out period, in no instance shall organ pro-
curement proceed until both the waiting period and
declaration of death are completed.
• Declaration of death is the responsibility of the pa-
tient’s treating care team. Assessment for cessation
of cardiorespiratory function is made using accepted
medical standards, in compliance with donor hospi-
tal policy. If withdrawal of support occurs outside the
operating room, the patient shall be quickly moved to
the operating room after the death pronouncement.
Organ procurement may be temporarily delayed if a
postmortem reperfusion technique such as normoth-
ermic extracorporeal membrane oxygenation (ECMO)
is used (see below).
• If the patient has not been declared dead within the
time frame stipulated by the local procurement proto-
col, then the donation is aborted and the patient is re-
turned to the ward/intensive care unit for comfort care
(1,23,26). The OPO coordinator shall document, on a
preprinted flow sheet, hemodynamic measurements
every minute, as well as the times of discontinuation
of mechanical ventilation, cessation of cardiorespira-
tory function, waiting period, declaration of death, inci-
sion and perfusion of each organ. After procurement,
careful assessment of this information is critical for
assessing ischemic injury (23,24).
Operative technique (liver, kidney and/or pancreas
procurement)
• An experienced donor procurement surgical team
shall procure organs from DCD donors. The senior
surgeon shall have reviewed the local OPO DCD pro-
tocol(s), be familiar with these ASTS DCD guidelines
and be an experienced donor surgeon.
• There shall be adequate planning and communication
with the donor coordinator(s) and operating room per-
sonnel.
• Each member of the surgical team shall behave profes-
sionally and courteously throughout the donor facility
stay and shall always exhibit mutual respect for the
hosting facility staff, even in the face of the often hec-
tic and demanding nature of DCD organ procurement.
• The super rapid recovery (see below) or premortem
cannulation (see below) techniques may be used for
DCD organ procurement.
• Most surgeons use some modification of the super
rapid recovery technique (32,33). Prior to withdrawal
of support, the donor is typically prepared and draped,
and the surgical instruments, preservation solution
and tubing are set up to facilitate rapid recovery. Fol-
lowing the waiting period and declaration of death,
the surgeons return to the operating room and expe-
ditiously perform lower midline laparotomy and aortic
cannulation. Ischemia time may be reduced by starting
the aortic flush and topical ice cooling immediately af-
ter cannulation. Thereafter, the thoracic or supraceliac
aorta is cross-clamped, and the vena cava is vented
into the right chest. It is easier to cross-clamp the aorta
in a dry field, but the vena cava should be vented first
if cross-clamping is not expeditious, in order to avoid
organ engorgement. The portal system is cannulated
in situ via the inferior mesenteric vein or the portal vein
may be flushed on the back table. The organs may be
removed en bloc or separately.
• The premortem cannulation technique decreases the
rush inherent with the super rapid recovery technique
and may decrease warm ischemia time, particularly if
withdrawal of support is performed outside the oper-
ating room. This technique requires cannulation of a
femoral artery and femoral vein prior to withdrawal of
support (33,34). Specific informed consent shall be ob-
tained if this technique is to be used (1–3,23,24,26).
Local anesthesia shall be used as appropriate. After
declaration of death, a cold preservation solution is
immediately infused via the femoral artery cannula,
and the femoral vein cannula is opened to gravity to
decompress the venous system. Thereafter, median
sternotomy and midline abdominal incisions are made
and the intraabdominal organs are topically ice cooled
and then removed en bloc or separately.
∗ A few centers use premortem cannulation in con-
junction with postmortem ECMO to restore the flow
of warm oxygenated blood to the intraabdominal or-
gans during the interval between death and organ
procurement, further facilitating unhurried organ pro-
curement and possibly improving graft function (35).
• Special care is required to avoid damage to vital struc-
tures during DCD organ procurement, whether super
rapid or premortem cannulation techniques are used.
There must be particular concern about the possibility
of aberrant arterial vasculature because all DCD vis-
ceral dissection is performed in a cold field without
2008 American Journal of Transplantation 2009; 9: 2004–2011
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blood flow (unless the ECMO technique is used) and
there are no opportunities to assess pulses (33).
• If the DCD pancreas is not going to be procured, then
the liver may be removed with the pancreatic head
to avoid transecting an aberrant right hepatic artery
and to minimize extraction time. The DCD liver and
pancreas may be removed en bloc. If the organs are to
be removed separately, the need to minimize ischemia
time and the desire to procure the pancreas need to
be balanced; it may be impractical to add whole-organ
pancreatectomy to hepatectomy during DCD recovery
in the face of unfavorable donor body habitus or long
warm ischemia time (33,36).
• As with DBD organ procurement, there shall be a dili-
gent search in both the abdominal and thoracic cav-
ities for any neoplastic or infectious processes that
may present risk for donor-related transmission.
• There shall be a low threshold for obtaining donor or-
gan biopsies, to exclude predictors of poor graft quality
such as centrilobular hepatic necrosis or intravascular
renal microthrombosis.
• Careful consideration of risks and benefits is neces-
sary when deciding whether or not to transplant a
DCD organ with additional extended criteria donor or
graft characteristics such as older donor age, hepatic
steatosis or glomerulosclerosis.
Ischemia times
• Efforts shall be made to minimize both warm and cold
ischemia times during DCD organ procurement and
transplantation (11,13,14,19,24,33).
• Controlled DCD liver transplantation beyond the fol-
lowing time frames may be associated with increased
complications:
∗ True warm ischemia time (interval between signif-
icant ischemic insult, such as a drop in mean arterial
pressure below 60 mmHg, and initiation of perfusion)
longer than 20–30 min (33,37).
∗ Total warm ischemia time (interval between discon-
tinuation of mechanical ventilation and initiation of per-
fusion) longer than 30–45 min (11,13,14,24,33).
∗ Cold ischemia time longer than 8–10 h (10,11,24).
• Controlled DCD kidney or pancreas transplantation be-
yond the following time frames may be associated
with increased complications:
∗ Total warm ischemia time longer than 45–60 min
(24,38).
∗ Cold ischemia time longer than 24 h for kidneys and
longer than 18 h for pancreata (24).
Machine perfusion
• Ex vivo machine perfusion of organs may improve
transplant outcomes.
• Pulsatile perfusion of DCD kidneys is used by many to
decrease vasospasm and also to exclude kidneys with
persistently high vascular resistance. Although insuf-
ficient scientific data are currently available to warrant
mandating that DCD kidneys be pumped (7), there
shall be a low threshold for using this technique in an
effort to decrease delayed graft function (19).
• Techniques for machine perfusion of liver and of lung
are currently investigational.
Recipient considerations
• The possibility of DCD organ transplantation shall
be discussed with transplant candidates during the
transplant evaluation process so that they have some
knowledge about this type of organ transplantation
(3,24).
• Transplant teams shall discuss the specific risks and
benefits of controlled DCD organ transplantation with
their patients. When pertinent, the possibility of biliary
complications (liver) or delayed graft function (kidney)
shall be disclosed (3,24,39,40).
Biliary issues
• DCD liver transplantation has been associated with
the development of ischemic biliary complications
(11,14–16). Although there is a paucity of scientific
evidence regarding optimal management of the biliary
system in controlled DCD liver donors, the following
strategies may reduce biliary complications and im-
prove outcomes:
∗ Perform an expeditious, in situ biliary flush to mini-
mize bile-induced epithelial damage; the common bile
duct and gallbladder shall be generously irrigated early
after initiating the cold flush (33).
∗ Limit the use of DCD livers with longer ischemia
times or from older donors (11,13,14,41–43).
∗ Consider arterial revascularization before or simul-
taneously with portal revascularization of DCD livers
(14,43).
∗ Consider the use of a T-tube to facilitate interro-
gation of the biliary tree and therapeutic intervention
(e.g. removal of biliary sludge and dilation of biliary
stricture(s) prior to cast formation) (33).
Cardiothoracic organs
Pioneering surgeons have recently performed DCD lung
transplants (44) and DCD heart transplants (45) with suc-
cess. There are issues unique to DCD cardiothoracic organ
procurement and transplantation in addition to those also
relevant to DCD abdominal organs. The ASTS anticipates
advances in the field of DCD cardiothoracic organ trans-
plantation. When sufficient information and consensus are
available, guidelines specific to cardiothoracic organs will
be added to this document.
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Conclusion
Best-practice guidelines for DCD organ transplantation will
evolve as experience in this field increases. The ASTS en-
courages procurement and transplantation of DCD organs
and continued research on ways to increase feasibility and
improve outcomes of DCD organ transplantation.
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